Aarey Drugs & Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Aarey Drugs & Pharmaceuticals has a total shareholder equity of ₹1.4B and total debt of ₹386.5M, which brings its debt-to-equity ratio to 28.5%. Its total assets and total liabilities are ₹2.7B and ₹1.4B respectively. Aarey Drugs & Pharmaceuticals's EBIT is ₹44.0M making its interest coverage ratio -11.7. It has cash and short-term investments of ₹14.9M.
Key information
28.5%
Debt to equity ratio
₹386.50m
Debt
| Interest coverage ratio | -11.7x |
| Cash | ₹14.90m |
| Equity | ₹1.36b |
| Total liabilities | ₹1.39b |
| Total assets | ₹2.75b |
Recent financial health updates
Recent updates
Earnings Not Telling The Story For Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) After Shares Rise 46%
Aug 30
Aarey Drugs & Pharmaceuticals Limited's (NSE:AAREYDRUGS) Shares May Have Run Too Fast Too Soon
Jul 16Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Apr 15Aarey Drugs & Pharmaceuticals (NSE:AAREYDRUGS) Has A Pretty Healthy Balance Sheet
Mar 22What Aarey Drugs & Pharmaceuticals Limited's (NSE:AAREYDRUGS) P/E Is Not Telling You
Dec 30Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) Shares Fly 25% But Investors Aren't Buying For Growth
Dec 29Calculating The Fair Value Of Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS)
Aug 20Financial Position Analysis
Short Term Liabilities: AAREYDRUGS's short term assets (₹2.5B) exceed its short term liabilities (₹1.4B).
Long Term Liabilities: AAREYDRUGS's short term assets (₹2.5B) exceed its long term liabilities (₹4.9M).
Debt to Equity History and Analysis
Debt Level: AAREYDRUGS's net debt to equity ratio (27.4%) is considered satisfactory.
Reducing Debt: AAREYDRUGS's debt to equity ratio has increased from 19.5% to 28.5% over the past 5 years.
Debt Coverage: AAREYDRUGS's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: AAREYDRUGS earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 20:49 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aarey Drugs & Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anil Burra | FirstCall Research |